Aspira Women's Health Files S-1 for Public Offering

TL;DR

Aspira Women's Health filing S-1, looks to raise cash via public markets.

AI Summary

Aspira Women's Health Inc. filed an S-1 registration statement on September 30, 2025, to register securities under the Securities Act of 1933. The company, formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems, is incorporated in Delaware and headquartered in Austin, Texas. The filing indicates a public offering of securities, though specific dollar amounts and dates for the offering are not detailed in this excerpt.

Why It Matters

This S-1 filing signals Aspira Women's Health Inc.'s intention to raise capital through the public markets, which could fund further development and expansion of its women's health diagnostics.

Risk Assessment

Risk Level: medium — S-1 filings are typically associated with new public offerings or significant corporate actions, which inherently carry market and execution risks.

Key Numbers

• 333-290633 — SEC File Number (Identifies this specific registration statement with the SEC.)
• 2835 — SIC Code (Indicates the company operates in the 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' industry.)

Key Players & Entities

• Aspira Women's Health Inc. (company) — Registrant
• Michael Buhle (person) — Chief Executive Officer and Chief Commercial Officer
• Vermillion, Inc. (company) — Former Company Name
• Ciphergen Biosystems Inc (company) — Former Company Name
• Abiotic Systems (company) — Former Company Name
• 333-290633 (dollar_amount) — SEC File Number

FAQ

From the Filing

0001493152-25-016373.txt : 20250930 0001493152-25-016373.hdr.sgml : 20250930 20250930170846 ACCESSION NUMBER: 0001493152-25-016373 CONFORMED SUBMISSION TYPE: S-1 PUBLIC DOCUMENT COUNT: 16 FILED AS OF DATE: 20250930 DATE AS OF CHANGE: 20250930 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences EIN: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1 SEC ACT: 1933 Act SEC FILE NUMBER: 333-290633 FILM NUMBER: 251361415 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 S-1 1 forms-1.htm S-1 As filed with the Securities and Exchange Commission on September 30, 2025 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ASPIRA WOMEN’S HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 2835 33-0595156 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 12117 Bee Caves Road, Building III, Suite 100 Austin, Texas 78738 (512) 519-0400 (Address, including zip code and telephone number, including area code of registrant’s principal executive offices) Michael Buhle Chief Executive Officer and Chief Commercial Officer Aspira Women’s Health Inc. 12117 Bee Caves Road, Building III, Suite 100 Austin, Texas 78738 (512) 519-0400 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: J. Eric Johnson Winston & Strawn LLP 800 Capitol Street, Suite 2400 Houston, TX 77002 Tel.: (713) 651-2647 Approximate date of commencement of proposed sale to the public: As soon as practicable after the date this registration statement becomes effective. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☒ If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ If